CytoImmune Therapeutics, Inc. President William Rosellini to Present at Upcoming Conferences

CytoImmune Therapeutics Welcomes Aleksey Krylov, Chief Financial Officer
July 16, 2021
CytoImmune Therapeutics, Inc. CMO Michael Caligiuiri, MD to Present at a KOL Webinar on Human Natural Killer (NK) Cell Immunotherapy
July 16, 2021

Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today that its President, Will Rosellini, will be presenting at the following industry conferences:

2nd Annual LifeSci Partners Private Company Summer Symposium
Event Details: Presentation by CytoImmune Therapeutics President William Rosellini, JD, MBA
Date & Time: Wednesday, July 21st at 1.30pm ET

SVB LeeRink Virtual Healthcare Conference
Event Details: Investor Meetings by CytoImmune Therapeutics President William Rosellini
Date & Time: Wednesday, July 21st and Thursday, July 22nd

About CytoImmune Therapeutics, Inc.

CytoImmune Therapeutics is a clinical-stage biotechnology company developing a portfolio of natural killer (NK) immunotherapies designed to utilize the power of the patient’s own immune system to eliminate cancer cells. CytoImmune is moving towards filing the Investigational New Drug (IND) applications for novel immunotherapy programs in both solid and hematological malignancies. The company anticipates having programs in human trials in the second half of 2021.


Name: Will Rosellini

SOURCE: CytoImmune Therapeutics